Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual Symposium
30 Março 2023 - 8:30AM
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology
company focused on the discovery and development of next generation
therapeutics for cancer patients, today announced that John Celebi,
president and chief executive officer, will participate in a panel
titled ‘Novel Approaches in Immunotherapy’ at Cantor Fitzgerald’s
Future of Oncology Virtual Symposium on Monday, April 3rd at 10.00
a.m. ET.
About Sensei BiotherapeuticsSensei
Biotherapeutics (Nasdaq: SNSE) is an immuno-oncology company
focused on the discovery and development of next-generation
therapeutics for cancer patients. Through its TMAb™ (Tumor
Microenvironment Activated biologics) platform, Sensei develops
conditionally active therapeutics designed to disable
immunosuppressive signals or activate immunostimulatory signals
selectively in the tumor microenvironment to unleash T cells
against tumors. Sensei’s lead investigational candidate is SNS-101,
a conditionally active antibody designed to block the V-domain Ig
suppressor of T cell activation (VISTA) checkpoint selectively
within the low pH tumor microenvironment, where VISTA acts as a
suppressor of T cells by binding the receptor PSGL-1. The company
is also developing SNS-102, a conditional binding monoclonal
antibody targeting V-Set and Immunoglobulin Domain Containing 4
(VSIG-4), as well as SNS-103, also a conditionally active
monoclonal antibody targeting ecto-nucleoside triphosphate
diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more
information, please visit www.senseibio.com, and follow the company
on Twitter @SenseiBio and LinkedIn.
Investor Contact:Michael
BiegaSenior Director, Investor RelationsSensei
Biotherapeuticsmbiega@senseibio.com
Media Contact:Chris RaileyTen
Bridge Communicationschris@tenbridgecommunications.com
Sensei Biotherapeutics (NASDAQ:SNSE)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Sensei Biotherapeutics (NASDAQ:SNSE)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024